Kenneth Dorshkind, Ph.D., was appointed as Interim Director of the UCLA Jonsson Comprehensive Cancer Center on October 1, 2015. He is a professor in the Department of Pathology and Laboratory Medicine at the David Geffen School of Medicine and also serves as academic associate director of the Broad Stem Cell Research Center.
Dorshkind has been involved in programmatic issues at the cancer center for the past 15 years. In 1999, he was named associate director of the Hematopoietic Malignancies Program Area and was promoted to director in 2001, a position he served in for 10 years. Prior to his appointment as Interim Director, he was the cancer center’s Director for Shared Resources.
Dorshkind earned his B.S. in biology and M.S. in Anatomy at the University of California, Davis, and received a Ph.D. in Biological Structure from the University of Washington, Seattle. He was a postdoctoral fellow at the Ontario Cancer Institute in Toronto, Canada, where his work focused on hematopoiesis and development of the immune system. These themes have been the focus of his research over the past 30 years, which has been continuously funded by grants from the National Institutes of Health. He is currently the recipient of an NIH MERIT award.
The current research focus of Dorshkind’s laboratory is on lymphocyte development from hematopoietic stem cells and how that process is regulated by micro environmental and systemic factors. His team has developed and used a variety of in vitro and in vivo systems to test the developmental potential of various hematopoietic progenitor cell populations. Dorshkind hopes that learning more about early lymphocyte development will provide a basis for understanding the development of certain blood cancers and reveal how age-related declines in lymphocyte production impact the immune system.
In addition to his cancer center activities, Dorshkind has served as a section editor of the Journal of Immunology, a member of the Leukemia and Lymphoma Society of America Career Development Review Subcommittee, and a frequent reviewer for the National Institutes of Health.